Implications of the 2026 Dyslipidemia Guidelines, Mechanical Thrombectomy in Ischemic Stroke, Safe Sleep Video Intervention via Text Messaging to Low-Income Families, and more

Hi, Linda.

This week starts with dyslipidemia and the new AHA/ACC guidelines released in March of twenty-twenty-six.

Dyslipidemia is one of the most important modifiable cardiovascular risk factors, and the new guidelines include updated recommendations on the management of dyslipidemia, both for primary and secondary prevention of atherosclerotic cardiovascular disease, or ASCVD.

In an original investigation, Dr. Anderson and colleagues looked at how the twenty-twenty-six AHA/ACC dyslipidemia guidelines change eligibility for primary prevention with statins in the US.

They used NHANES data from twenty-seventeen through twenty-twenty-three and analyzed more than forty-three hundred participants, which represented just over a hundred and fifty-four million adults aged thirty to seventy-nine years without known ASCVD.

They estimated that eighty-seven point five million adults, or fifty-six point six percent of this population, would now be statin-eligible.

That includes nearly twenty-two million adults who are newly eligible.

Eligibility for statins rose sharply with age, including more than ninety-three percent among adults aged seventy to seventy-nine years.

Newly eligible adults were generally lower risk, with a mean estimated ten-year ASCVD risk of three point one percent, compared with six point one percent among those previously eligible.

The takeaway is straightforward.

The new dyslipidemia guidelines substantially expand the population that is eligible for statins for primary prevention, largely among younger people and low-risk adults.

Also on the topic of dyslipidemia, Dr. Peng and colleagues authored a research letter assessing shifts in cardiovascular risk assessment from the pooled cohort equations, which had been standard tools for estimating the ten-year risk, to the twenty-twenty-three prevent equations, now endorsed by the new twenty-twenty-six guidelines.

The authors used NHANES data from nineteen-ninety-nine through March twenty-twenty to study over twenty-four thousand adults aged forty to seventy-nine years, a total of about ninety-eight point five million US adults.

Overall, twenty-one point five percent were reclassified into a different ten-year risk category.

Of those who were reclassified, fourteen point two percent moved to a lower risk category, and seven point three percent moved to a higher risk category.

The proportion of individuals with borderline risk classification increased from twelve point six percent to eighteen point four percent, while indeterminate and high risk both decreased.

Reclassification to a lower risk category was most common among men, non-Hispanic Black adults, and current smokers.

Even with this reclassification, the proportion of individuals who are recommended for lipid-lowering therapy stayed about the same in the full cohort, forty-nine point six percent versus forty-nine point four percent.

This guideline update shifts toward more nuanced and individualized risk recommendations.

So the practical message is that this new approach changes who sits with which risk bucket, but not the overall number likely to be treated.

Yes, that's an important distinction.

Sticking with the topic of dyslipidemia, we have another research letter, this one from Dr. Abu-Hosham and colleagues that asks how many US adults are above the new LDL cholesterol goals.

The authors used data from NHANES from twenty-twenty-one to twenty-twenty-three, which included more than twenty-three hundred participants and represented nearly a hundred and seventy-eight million US adults.

In terms of primary prevention, thirty-two point two percent were above guideline LDL-C goals.

That climbed with risk from nine point nine percent among low-risk adults to sixty-three point six percent in those with borderline or intermediate risk, and eighty-two point seven percent in adults with high risk.